-
Mashup Score: 11A low-footprint, fluorescence-based bacterial time-kill assay for estimating dose-dependent cell death dynamics - 2 month(s) ago
Dose-response curves that describe the relationship between antibiotic dose and growth rate in bacteria are commonly measured with optical density (OD) based assays. While being simple and high-throughput, any dose-dependent cell death dynamics are obscured, as OD assays in batch culture can only quantify a positive net change in cells. Time-kill experiments can be used to quantify cell death rates, but current techniques are extremely resource-intensive and may be biased by residual drug carried over into the quantification assay. Here, we report a novel, fluorescence-based time-kill assay leveraging resazurin as a viable cell count indicator. Our method improves upon previous techniques by greatly reducing the material cost and being robust to residual drug carry-over. We demonstrate our technique by quantifying a dose-response curve in Escherichia coli subject to cefotaxime, revealing dose-dependent death rates. We also show that our method is robust to extracellular debris and cell
Source: www.biorxiv.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 1TET2 mutation as prototypic clonal hematopoiesis lesion - 2 month(s) ago
Loss of function TET2 mutation (TET2MT) is one of the most frequently observed lesions in clonal hematopoiesis (CH). TET2 a member TET-dioxygenase fam…
Source: www.sciencedirect.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 11Blood-based tests for multicancer early detection (PATHFINDER): a prospective cohort study - 7 month(s) ago
Multicancer early detection (MCED) blood tests can detect a cancer signal from circulating cell-free DNA (cfDNA). PATHFINDER was a prospective cohort …
Source: www.sciencedirect.comCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 122023 FASTRO Recipients - American Society for Radiation Oncology (ASTRO) - American Society for Radiation Oncology (ASTRO) - 7 month(s) ago
ASTRO is proud to announce the 2023 Class of ASTRO Fellows:
Source: www.astro.orgCategories: Latest Headlines, Oncologists1Tweet
-
Mashup Score: 2Home | VeloSano - 8 month(s) ago
Latin for “swift cure,” VeloSano is Cleveland Clinic’s premier fundraising initiative in which 100% of every dollar raised supports lifesaving cancer research at Cleveland Clinic and Cleveland Clinic Children’s. Since its inception in 2014, over $37 million has been raised and has advanced over 200 cancer research projects.
Source: velosano.orgCategories: Hem/Oncs, Latest HeadlinesTweet-
A great day for VeloSano 10!! @bikeVeloSano. 🚴♀️🚴 🚴♂️ Always amazed at the awesome turnout from so many volunteers 🙏 (like @ShinjiniGanguly and @huitingruan #MianLab) Thank you!! Not to late to support riders by going to https://t.co/yTtGV61DXu #CleClinicCancer https://t.co/o06o6DeBeQ https://t.co/yCuXvuYqa3
-
-
Mashup Score: 2Home | VeloSano - 8 month(s) ago
Latin for “swift cure,” VeloSano is Cleveland Clinic’s premier fundraising initiative in which 100% of every dollar raised supports lifesaving cancer research at Cleveland Clinic and Cleveland Clinic Children’s. Since its inception in 2014, over $37 million has been raised and has advanced over 200 cancer research projects.
Source: velosano.orgCategories: Latest Headlines, Oncologists1Tweet
-
Mashup Score: 3
We previously reported that persons experiencing homelessness (PEH) are significantly less likely to undergo prostate-specific antigen (PSA) testing than persons not experiencing homelessness (non-PEH; 13% vs 34%; p < 0.001) [1]. The purpose of this study was to determine if lower use of PSA testing in PEH results in more advanced prostate cancer.
Source: www.europeanurology.comCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 4Antigen presentation in cancer — mechanisms and clinical implications for immunotherapy - Nature Reviews Clinical Oncology - 11 month(s) ago
Immune-checkpoint inhibitors (ICIs) and other immunotherapies have revolutionized the treatment of patients with cancer. Nonetheless, most patients do not derive durable benefit, indicating a need for biomarkers to guide treatment selection. In this Review, the authors describe the role of antigen presentation in response to ICIs and other immunotherapies, with a focus on the role of molecular…
Source: NatureCategories: Latest Headlines, Oncologists1Tweet
-
Mashup Score: 3AI-Generated R.E.N.A.L.+ Score Surpasses Traditional Methods for Prediction of Oncologic Outcomes - 12 month(s) ago
AI-generated model bests predictive abilities of human experts
Source: Consult QDCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 6Using a gene signature to predict cancer patient's response to chemotherapy agent cisplatin - 1 year(s) ago
Researchers at Cleveland Clinic have taken an important step in predicting which treatment will work for individual cancer patients.
Source: News-Medical.netCategories: Hem/Oncs, Latest HeadlinesTweet
RT @CancerConnector: Eshan is on a roll! New preprint from this future #physicianscientist @cwrumstp https://t.co/JRKplzXYeC Ever want…